Citigroup’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-143,000
| Closed | -$12.1M | – | 7965 |
|
|
2019
Q4 | $12.1M | Buy |
143,000
+38,300
| +37% | +$2.55M | 0.01% | 1321 |
|
|
2019
Q3 | $5.24M | Buy |
104,700
+25,500
| +32% | +$1.02M | ﹤0.01% | 1895 |
|
|
2019
Q2 | $2.89M | Sell |
79,200
-7,300
| -8% | -$238K | ﹤0.01% | 2443 |
|
|
2019
Q1 | $2.42M | Sell |
86,500
-5,100
| -6% | -$120K | ﹤0.01% | 2473 |
|
|
2018
Q4 | $1.75M | Buy |
91,600
+65,600
| +252% | +$1.53M | ﹤0.01% | 2797 |
|
|
2018
Q3 | $778K | Sell |
26,000
-700
| -3% | -$26.4K | ﹤0.01% | 3772 |
|
|
2018
Q2 | $980K | Buy |
26,700
+22,000
| +468% | +$715K | ﹤0.01% | 3383 |
|
|
2018
Q1 | $155K | Sell |
4,700
-19,800
| -81% | -$619K | ﹤0.01% | 5213 |
|
|
2017
Q4 | $670K | Sell |
24,500
-4,500
| -16% | -$139K | ﹤0.01% | 3780 |
|
|
2017
Q3 | $1.07M | Sell |
29,000
-21,000
| -42% | -$774K | ﹤0.01% | 3291 |
|
|
2017
Q2 | $1.9M | Sell |
50,000
-54,400
| -52% | -$2.42M | ﹤0.01% | 2642 |
|
|
2017
Q1 | $5.11M | Buy |
104,400
+73,400
| +237% | +$3.35M | ﹤0.01% | 1652 |
|
|
2016
Q4 | $1.05M | Sell |
31,000
-65,000
| -68% | -$2.31M | ﹤0.01% | 3639 |
|
|
2016
Q3 | $3.62M | Buy |
96,000
+79,500
| +482% | +$3M | ﹤0.01% | 1970 |
|
|
2016
Q2 | $555K | Sell |
16,500
-11,800
| -42% | -$416K | ﹤0.01% | 3569 |
|
|
2016
Q1 | $899K | Buy |
28,300
+13,000
| +85% | +$425K | ﹤0.01% | 3458 |
|
|
2015
Q4 | $571K | Sell |
15,300
-1,700
| -10% | -$64.2K | ﹤0.01% | 3714 |
|
|
2015
Q3 | $646K | Buy |
17,000
+7,900
| +87% | +$277K | ﹤0.01% | 3496 |
|
|
2015
Q2 | $260K | Buy |
+9,100
| New | +$253K | ﹤0.01% | 4232 |
|
Other funds holding MDCO
Citigroup's MDCO Position: Q1 2020 in Review
Citigroup sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 2,541,983 shares — an estimated $216M sold.
Citigroup first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $216M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Citigroup reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Citigroup sold 2,541,983 Medicines Co shares in Q1 2020, an estimated $216M.
- Citigroup first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Citigroup's Medicines Co position peaked at $216M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Citigroup's 13F filing for Q1 2020, filed 12 May 2020.